After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna probably won't go down in history as a one-hit wonder, however. The biotech has a rich and diverse pipeline of candidates that could fuel a recovery in its stock performance.

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Moderna stock rallied 9% yesterday, after it launched phase 2/phase 3 clinical trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck. As per an earlier ...

Moderna stock (NASDAQ: MRNA) has rallied from around $104 per share at the end of 2020, to about $485 as of Monday, an increase of over 4.5x. This compares to the S&P 500 which is up by just about ...

Moderna's Q1 2022 financial performance was better than expected, but MRNA didn't raise full-year 2022 guidance. See if MRNA stock is a buy, sell, or hold.

Moderna stock declined by about 30% over the last week (five trading days) following the company’s weaker than expected Q3 2021 results. While Moderna’s revenue for Q3 grew by almost 13% ...